Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.769 EUR | +2.26% | -2.04% | +78.84% |
Mar. 11 | Sensorion: study results in hearing loss | CF |
Mar. 11 | Sensorion Meets Primary Endpoint for Sens-401 Phase 2A Clinical Study for Residual Hearing Preservation | CI |
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Analyst opinion has improved significantly over the past four months.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+78.84% | 224M | - | ||
+9.29% | 45.97B | B | ||
+52.73% | 43.93B | A | ||
+8.00% | 42.34B | B- | ||
-8.78% | 28.27B | C | ||
+18.66% | 27.18B | B- | ||
-21.42% | 19.44B | B | ||
+14.92% | 13.83B | C+ | ||
+31.42% | 12.4B | C+ | ||
+6.52% | 11.45B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock
- Equities
- Stock Sensorion - Euronext Paris
- Ratings Sensorion